Biohaven
This sponsor has funded 2 studies across 1 countries.
| EU PAS ID | Status | RMP requirement | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|---|
| 45356 | Ongoing | Not included in RMP | A Prospective, Registry-based, Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant: The Migraine... | Yes | No |
| 45952 | Ongoing | Non-EU RMP-only | Retrospective Cohort Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy | Yes | No |
PAS by Risk Management Plan (RMP) requirement
Biohaven
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Biohaven
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Biohaven
1 Study countries specified are the following:
- United States